Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nizatidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 known ✓ | P25021 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.59 |
| ▸ | ATP4A | P20648 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | ATP4B | P51164 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nizatidine SCHEMBL13575816 | 1.00 | ACHE (1.00) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL769 | 1.00 | ACHE (1.00) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL9241933 | 1.00 | ACHE (1.00) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL28723397 | 0.99 | ACHE (0.98) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL5041217 | 0.99 | ACHE (0.98) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL6239553 | 0.98 | ACHE (0.96) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL28102651 | 0.97 | ACHE (0.94) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| SCHEMBL10425830 | 0.95 | ACHE (0.91) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| SCHEMBL4344477 | 0.95 | ACHE (0.90) | ACHEHRH2MEN1SLC22A1ABCB11 | |
| Nizatidine SCHEMBL158261 | 0.94 | ACHE (0.88) | ACHEHRH2MEN1SLC22A1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15471 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-12544376-B2 | Amorphous solid dispersions of dasatinib and uses thereof | HANDA THERAPEUTICS, LLC (US) | 2026-02-10 | — | — | US | claimed |
| US-12496295-B2 | Veterinary pharmaceutical compositions for direct systemic introduction | NEWMARKET PHARMACEUTICALS LLC (US) | 2025-12-16 | — | — | US | claimed |
| US-20250367126-A1 | SOFTGEL CAPSULE COMPRISING A H2 RECEPTOR ANTAGONIST | KENVUE BRANDS LLC (US) | 2025-12-04 | — | — | US | claimed |
| US-12480096-B2 | Clinical gene signature-based human cell culture model and uses thereof | UNIVERSITE DE STRASBOURG (FR) | 2025-11-25 | — | — | US | claimed |
| EP-4630401-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | Rutgers, the State University of New Jersey (US) | 2025-10-15 | — | — | EP | claimed |
| US-4915954-A | Dosage form for delivering a drug at two different rates | ALZA CORPORATION (US) | 1990-04-10 | — | — | US | claimed |
| US-4783337-A | Osmotic system comprising plurality of members for dispensing drug | ALZA CORPORATION (US) | 1988-11-08 | — | — | US | claimed |
| EP-0275669-A1 | Use of heterocyclic derivatives for the manufacture of medicaments | GLAXO GROUP LIMITED (GB) | 1988-07-27 | — | — | EP | claimed |
| CN-86108424-A | The synthetic method of nizatidine | — | 1987-08-05 | — | — | CN | claimed |
| EP-0230127-A1 | Synthesis of nizatidine | ELI LILLY AND COMPANY (US) | 1987-07-29 | — | — | EP | claimed |
| EP-0049618-B1 | IMPROVEMENTS IN OR RELATING TO 2,4-DISUBSTITUTED THIAZOLE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1985-08-14 | — | — | EP | claimed |
| EP-0116452-A2 | Improvements in or relating to the synthesis of nizatidine | ELI LILLY AND COMPANY (US) | 1984-08-22 | — | — | EP | claimed |
| US-4382090-A | N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds | ELI LILLY AND COMPANY (US) | 1983-05-03 | — | — | US | claimed |
| US-4375547-A | ANTIHISTAMINES, 'I RECEPTOR ANTAGONISTS, ANTISECRETORY AGENTS | ELI LILLY AND COMPANY (US) | 1983-03-01 | — | — | US | claimed |
| EP-0049618-A1 | Improvements in or relating to 2,4-disubstituted thiazole derivatives | ELI LILLY AND COMPANY (US) | 1982-04-14 | — | — | EP | claimed |